MD Anderson Cancer Center Joins ITUS Early Cancer Detection Biomarker Study

LOS ANGELES, CA -- (Marketwired) -- 12/07/16 -- ITUS Corporation (NASDAQ: ITUS) today announced that it has enrolled the MD Anderson Cancer Center at Cooper Hospital in southern New Jersey to be a part of its ongoing cancer biomarker study.

"MD Anderson is one of the most well respected names when it comes to cancer," said Dr. Amit Kumar, ITUS's Executive Chairman. "Patient blood samples provided by MD Anderson will assist us in achieving the critical mass that we need to further validate our technology and test benign conditions as we prepare to begin for discussions with regulators."

MD Anderson is world-renowned for developing and using frontline diagnostic technology that helps physicians pinpoint each patient's unique cancer and tailor treatment for the best possible outcome. Devoted exclusively to cancer patient care, research, education and prevention, MD Anderson is one of the world's most respected names when it comes to cancer.

ITUS Corporation

The Company is developing a platform called Cchek™, a series of non-invasive, blood tests for the early detection of solid tumor based cancers, which is based on the body's immunological response to the presence of a malignancy. Additional information is available at www.ITUScorp.com.

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our Annual Report on Form 10-K for the fiscal year ended October 31, 2016 as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

ITUS Corporation: FOCUSED ON INNOVATION™

Contact:
Dean Krouch
310-484-5184
dkrouch@ITUScorp.com

Source: ITUS Corporation

Released December 7, 2016